Dr. Eric R. Wiedower, DO
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 16
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 983
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
TN license 3015 · MS license 24301
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Baptist Memorial Hospital Desoto Southaven, MS
- Regional One Health Memphis, TN
- Methodist Healthcare - Olive Branch Hospital Olive Branch, MS
- St Francis Hospital Memphis, TN
- Baptist Memorial Hospital North Ms Oxford, MS
Medical groups
- The West Clinic P.c. (118 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 983
- Services billed
- 274,757
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 62,080 | 51 |
| Injection, nivolumab, 1 mg | 19,080 | 16 |
| Injection, pembrolizumab, 1 mg | 17,400 | 26 |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 16,380 | 18 |
| Injection, oxaliplatin, 0.5 mg | 15,800 | 15 |
| Injection, ferric carboxymaltose, 1 mg | 13,500 | 17 |
| Injection, paclitaxel, 1 mg | 12,076 | 25 |
| Injection, dexamethasone sodium phosphate, 1 mg | 5,746 | 99 |
| Injection, denosumab, 1 mg | 4,800 | 40 |
| Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | 3,770 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Germantown, TN | 141 |
| Eliquis (apixaban) Other prescribers in Germantown, TN | 107 |
| Dexamethasone Other prescribers in Germantown, TN | 103 |
| Prochlorperazine Maleate Other prescribers in Germantown, TN | 93 |
| Prednisone Other prescribers in Germantown, TN | 75 |
| Hydroxyurea Other prescribers in Germantown, TN | 72 |
| Allopurinol Other prescribers in Germantown, TN | 63 |
| Jakafi (ruxolitinib phosphate) | 59 |
| Gabapentin Other prescribers in Germantown, TN | 56 |
| Xarelto (rivaroxaban) Other prescribers in Germantown, TN | 52 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 39 companies reported 166 payments worth $4,203 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $1,251 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $327 |
| Janssen Biotech, Inc. | $298 |
| GlaxoSmithKline, LLC. | $289 |
| Merck Sharp & Dohme LLC | $249 |
| Gilead Sciences, Inc. | $144 |
| E.r. Squibb & Sons, L.l.c. | $137 |
| Celgene Corporation | $132 |
| Food and Beverage | $3,088 |
|---|---|
| Long term medical supply or device loan | $1,098 |
| Education | $15.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation Jan 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Feb 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Mar 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation May 15, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Apr 24, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Jun 12, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Aug 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Oct 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Nov 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Dec 30, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
All 13 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation Dec 30, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Nov 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Legend Biotech USA Inc. Oct 27, 2025 | Education CARVYKTI · Oncology · in-kind | $15.99 |
| Novartis Pharmaceuticals Corporation Oct 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Sep 19, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Aug 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Jul 25, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Jun 12, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation May 15, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Apr 24, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Mar 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Feb 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Jan 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.